glycaemic control, 6 although no significant effect on CV outcomes was observed after a median follow-up of 10 years. 7 Body weight control is, therefore, an important component of an individualized, multifactorial approach to diabetes management, and this is highlighted in recent treatment guidelines. [8] [9] [10] Weight loss is a recognized outcome of glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy and all currently available GLP1RAs (albiglutide, dulaglutide, exenatide, liraglutide and lixisenatide)
promote weight loss in subjects with type 2 diabetes to varying extents. 11, 12 Semaglutide (Novo Nordisk, Denmark) is a new glucagon-like peptide-1 (GLP-1) analogue for the treatment of type 2 diabetes, with 94% amino acid sequence homology to native GLP-1 and with a halflife of approximately 1 week. 13, 14 In the SUSTAIN clinical trial programme, consisting of seven global clinical trials including more than 8000 adults with type 2 diabetes, semaglutide demonstrated superior reductions from baseline in both HbA1c and body weight versus placebo and active comparators (sitagliptin, exenatide extended release
[ER], insulin glargine and dulaglutide). [15] [16] [17] [18] [19] [20] [21] The SUSTAIN 6 trial also demonstrated a reduction in the risk of CV outcomes with semaglutide versus placebo over 2 years in subjects at high risk for CV events. were not available at the time of this analysis, and have therefore not been included. 21 
| MATERIALS AND METHODS

| Study design
We conducted a post hoc efficacy analysis by trial using all subjects in the global phase 3a SUSTAIN 1 to 5 randomized clinical trial programme. The study designs of these trials are summarized in Table S1 (see the Supporting Information for this article) and have been reported previously. [15] [16] [17] [18] [19] The programme included subjects spanning the diabetes continuum of care: drug-naïve (SUSTAIN 1); on metformin and/or thiazolidinediones (SUSTAIN 2); on 1 to 2 therapies com- Two semaglutide maintenance dose levels (0.5 and 1.0 mg onceweekly) were used in each trial except for SUSTAIN 3, in which only the 1.0 mg dose was used. Semaglutide was administered using a prefilled pen injection device. Semaglutide-treated subjects followed a fixed-dose escalation regimen to improve GI tolerability. The semaglutide 0.5 mg maintenance dose was reached after 4 weeks of semaglutide 0.25 mg once-weekly, and the semaglutide 1.0 mg maintenance dose was reached after 4 weeks of semaglutide 0.25 mg once-weekly, followed by 4 weeks of semaglutide 0.5 mg once-weekly.
| Patient population
The key inclusion/exclusion criteria were similar across the SUSTAIN failure New York Heart Association class IV. [15] [16] [17] [18] [19] All trials were conducted in compliance with the International Conference on Harmonization Good Clinical Practice guidelines 22 and the Declaration of Helsinki. 23 The protocol was approved by local ethics committees and institutional review boards. Written informed consent was obtained from all subjects before trial commencement.
| Study endpoints and assessments
In the pre-planned analyses, the key endpoints were similar across all of the SUSTAIN 1 to 5 trials. The primary endpoint was the change in
HbA1c from baseline to end of treatment (30 or 56 weeks). The confirmatory secondary endpoint was the change in body weight from baseline to end of treatment (30 or 56 weeks). Other secondary endpoints presented in these analyses were the proportions of subjects achieving ≥5% or ≥10% weight loss, and safety parameters including AEs.
15-19
| Post hoc analyses
Analyses were based on data from subjects while they were on treatment without using rescue medication. 3 | RESULTS
| Subject disposition and baseline characteristics
Overall, 3918 subjects with type 2 diabetes who were treatmentnaïve (SUSTAIN 1) or on a background of glucose-lowering drugs (metformin, sulfonylureas, thiazolidinediones in SUSTAIN 2 to 4 and basal insulin AE metformin in SUSTAIN 5) were randomized to onceweekly subcutaneous (s.c.) semaglutide 0.5 or 1.0 mg or comparator treatment ( Table 1) .
A total of 3899 (99.5%) subjects were exposed to their investigational product and 92.5% to 95.7% completed the trials (whether they were on or off the trial medication). Overall, the proportions of subjects who discontinued treatment prematurely were 10.6% to 13.5%
in the semaglutide 0.5 mg group, 12.2% to 20.3% in the semaglutide 1.0 mg group, and 7.2% to 21.0% across the comparator groups ( Baseline characteristics were broadly similar between subjects across treatment groups (Table 1) , with differences between trials reflecting the eligibility criteria. Baseline age and BMI were similar across the five trials. Differences in diabetes duration were observed, which reflected the stage the subjects were at in the continuum of type 2 diabetes care.
| Change from baseline in body weight and related endpoints
Across the SUSTAIN trials, semaglutide consistently and significantly reduced body weight from baseline versus comparators in subjects receiving different background medications ( Figure 1A ). [15] [16] [17] [18] [19] The effect was consistent across all BMI subgroups; body weight decreased by 2.5 to 5.7 kg and 2.0 to 7.9 kg with semaglutide 0.5 and 1.0 mg, respectively, versus a 1.5 kg gain to a 3.7 kg loss with comparators ( Figure 1A ).
In general, greater absolute weight loss in kg was observed in subjects with higher baseline BMI for both semaglutide doses as well as for comparators, with the exception of insulin glargine in SUSTAIN 4. In this trial, the weight increase for insulin glargine was independent of baseline BMI, whereas the weight loss for semaglutide 1.0 mg was BMI-dependent, leading to a significant interaction (P = .0046). There was no significant interaction between BMI and treatment difference with other comparators. Weight loss with semaglutide 1.0 mg was consistently greater than with comparators across all BMI subgroups, with the differences statistically significant in all but one case (P < .05; Figure 1A ). Weight loss with semaglutide 0.5 mg was also consistently and significantly greater than with comparators across all subgroups, apart from a few cases where statistical significance was not reached (P < .05; Figure 1A ).
3.3 | Proportion of subjects achieving ≥5% or ≥10% weight loss
As previously reported in the individual SUSTAIN 1 to 5 trials, 15-19 a significantly greater proportion of semaglutide-treated subjects achieved ≥5% and ≥10% weight loss versus comparators ( Figure S1 , Supporting Information). Significantly greater proportions of subjects achieved weight loss ≥5% and ≥10% with both semaglutide doses versus comparators across all BMI subgroups (P < .05; Figure S1 , Supporting Information). This effect was more marked with semaglutide 1.0 mg than with 0.5 mg.
The differences in subjects achieving ≥10% weight loss reached statistical significance in most BMI subgroups for semaglutide 1.0 mg, but less consistently for semaglutide 0.5 mg ( Figure S1B , Supporting Information). In SUSTAIN 1, the difference in subjects achieving this weight loss response was not significant.
Among heavier subjects (baseline BMI ≥35 kg/m 2 ), the proportions achieving ≥5% weight loss were 30% to 49% and 47% to 68% of those receiving semaglutide 0.5 and 1.0 mg, respectively, versus 6% to 27% receiving comparator treatments. These results were broadly similar to the overall population and to those with a baseline BMI <25 kg/m 2 , with the exception of SUSTAIN 3 (10% threshold) and SUSTAIN 5 (5% and 10% thresholds), in which proportionately fewer subjects achieved these targets than in those with low baseline BMI ( Figure S1 , Supporting Information). There were, however, no overall BMI-dependent effects on relative weight loss across the trials. 
| Weight loss by GI AEs-post hoc analysis
| Direct and indirect effects on weight lossmediation analysis
The mediation analyses of direct and indirect effects revealed that only a very small proportion (0.07 to 0.5 kg) of weight loss was explained by nausea or vomiting (indirect effects) (Figure 2 ).
Therefore, of the overall greater weight loss observed with semaglutide versus comparators (2.3 to 6.3 kg), most of this reduction (2.2 to 5.9 kg) was not explained by nausea or vomiting (direct effects) (Figure 2 ).
| Safety
Overall, semaglutide was well tolerated across the SUSTAIN 1 to 5 trials, and no unexpected safety issues were identified. [15] [16] [17] [18] [19] GI AEs were generally reported at higher rates with semaglutide than with comparators, and higher rates were observed in the subgroups with comparatively lower, rather than higher, baseline BMI ( Table 2 ). Rates of premature treatment discontinuation with semaglutide were also higher in subjects with lower baseline BMI compared with those with a higher baseline BMI ( Table 2 ).
| DISCUSSION
The In direct comparisons of GLP1-RAs, weight loss was significantly greater with liraglutide 1.8 mg than exenatide ER, albiglutide, dulaglutide and lixisenatide, and similar to that of exenatide twice-daily.
11,12
While a phase 3 trial comparing semaglutide and liraglutide is not currently available, phase 2 results suggest that semaglutide treatment may be expected to show equivalent or greater weight loss.
33
SUSTAIN 3 was the only trial analyzed here that compared semaglutide with another GLP-1RA. 17 In addition, the recently published SUSTAIN 7 trial compared semaglutide 0.5 mg versus dulaglutide 0.75 mg and semaglutide 1.0 mg versus dulaglutide 1.5 mg, all onceweekly. 21 In both of these trials, semaglutide demonstrated significantly greater weight loss than the other two GLP-1RAs, both in terms of absolute weight loss and the proportions of subjects achieving ≥5% weight loss. In SUSTAIN 3, the difference compared with exenatide ER was present across all BMI groups. This is despite the three agents ostensibly sharing the same mechanism of action.
The reason behind these differences is unclear. In the case of exenatide ER, it may be related to its exendin-4-derived structure, which has a much lower amino acid sequence homology to native human GLP-1 than semaglutide. This may confer different binding characteristics to the GLP-1 receptor.
11,17
The safety findings were similar to those reported with semaglutide in the individual SUSTAIN 1 to 5 trials. [15] [16] [17] [18] [19] In general, the GI disorder AE rate was higher with semaglutide than with comparators, with more GI AEs occurring in the lower versus higher baseline BMI subgroups. This is also in line with studies of other GLP-1RAs, in which the most commonly reported AEs were typically GI in nature and included nausea, vomiting and diarrhea. 11, 12 The relationship between nausea-or vomiting-related events and semaglutide-induced weight loss was assessed in a mediation analysis.
We anticipated that the results of the analysis would help to determine the mechanisms of weight loss observed with semaglutide and other GLP-1RA therapies and, in particular, whether nausea and vomiting are directly involved. Mediation analysis (i.e. how a third variable affects the relationship between the two other variables) is commonly used to elucidate the causal mechanism behind a treatment effect on a given outcome, separating an indirect effect mediated by a particular variable from the remaining direct effect. 24, 34 We used this method to identify the specific proportion of the weight loss attributable to nausea or vomiting Treatment effect
Based on 'on-treatment without rescue medication' data from subjects in the full analysis set, with missing data imputed from a mixed model for repeated measurements. Direct or indirect effects were estimated using natural effect models with imputation-based estimation, including the interaction between treatment and any nausea or vomiting together with the baseline variables of body weight, country and stratification factors (for SUSTAIN 4 and 5 only) as main effects, assuming no interaction between natural effects and baseline variables (confidence intervals were percentile bootstrap estimates). The effect of GLP-1RAs on weight loss has previously been shown to be centrally mediated, and may include a direct effect on the hypothalamus. 35 Increased activation in the brain stem and proopiomelanocortin (POMC)/cocaine-and amphetamine-regulated transcript (CART)-producing neurons in the hypothalamus, and in other brain regions, is associated with controlling meal termination and decreased food intake in animal models, 36,37 although this has not been shown directly in humans. Nevertheless, these data are consistent with infusion studies with native GLP-1 in healthy/normal weight and obese individuals, which suggest that the observed reduction in energy intake and appetite 38 is not a consequence of nausea.
39
A recent 12-week placebo-controlled trial of 30 obese adults has indicated a key role for reduced energy intake in semaglutide-induced weight loss. 40 The likely identified mechanisms were: reduced appetite and food cravings, better control of eating, and a lower preference for fatty, energy-dense foods. 40 
